Organizational Disclosures
about the aan
Below is a breakdown of industry contribution towards the consolidated revenue of the Academy (American Academy of Neurology and American Academy of Neurology Institute). Industry includes for-profit entities that develop, produce, market, or distribute drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, and alleviate health conditions (e.g., pharmaceutical and medical device/software manufacturers and other for-profit health services/product providers). Industry does not include non-profit entities, entities outside of the health care sector, or entities through which physicians provide clinical services directly to patients (e.g., hospitals, medical centers, publishers, foundations, recruiters, insurance providers).
2022 External (Industry) Support
- Total Industry Revenue: $9,465,419
- Percentage of Total Academy Revenue: 14%
- Educational Grants: $453,000
- Sponsorship: $5,077,794
- Exhibit Space: $2,244,625
- Industry Roundtable Membership Dues: $1,690,000
Total contribution by company in 2022 (Greater than $100K):
AbbVie, Inc.
Actelion Pharmaceuticals Ltd..
Alexion Pharmaceuticals
Allergan, Inc.
Amgen
ANI Pharmaceuticals, Inc.
argenx
AveXis, Inc.
Biogen
Biohaven Pharmaceuticals
Bristol Myers Squibb
Eisai Inc.
Eli Lilly and Company
EMC Sorono, Inc.
Genentech
Idorsia Pharmaceuticals US, Inc.
Lundbeck
Neurocrine Biosciences
Novartis Pharmaceuticals
Sanofi Genzyme
Sarepta Therapeutics
SK life science
Supernus Pharmaceuticals, Inc.
TG Therapeutics
UCB, Inc.
Viela Bio
View the Principles Governing Academy Relationships with External Sources of Support
View the Council of Medical Specialty Societies Code for Interactions with Companies